Related Experiment Videos
Anemia in heart failure:current evidence and challenges
1Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Reviews in Cardiovascular Medicine
|July 3, 2007
Summary
Anemia in heart failure patients worsens outcomes. While treatments like erythropoiesis-stimulating agents (ESAs) show promise for improving exercise capacity, their long-term safety and efficacy require further study.
Area of Science:
- Cardiology
- Hematology
- Nephrology
Background:
- Anemia is prevalent in heart failure (HF) patients, correlating with reduced function and poor prognosis.
- The pathophysiology and natural history of anemia in chronic HF remain unclear.
- Optimal treatment targets for
Purpose of the Study:
- To review the current understanding of anemia in heart failure.
- To discuss potential therapeutic strategies and ongoing research.
- To highlight uncertainties in management and research needs.
Main Methods:
- Literature review of anemia in heart failure.
- Analysis of current therapeutic approaches and investigational agents.
- Discussion of ongoing clinical trials and research directions.
Main Results:
- Anemia in HF is associated with worse functional capacity and prognosis.
- Reversible causes like renal insufficiency and deficiencies should be evaluated.
- Erythropoiesis-stimulating agents (ESAs) show potential for improving exercise capacity and quality of life in early studies.
Conclusions:
- Further research is crucial to clarify the safety and efficacy of ESAs in HF patients.
- Ongoing trials and iron supplementation studies aim to define optimal treatment strategies.
- Addressing anemia in HF may improve patient outcomes, but requires careful management and further investigation.
Related Concept Videos
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...